# Mario Negri Institute for Pharmacological Research: Phase 3 study in Breast Cancer, Interstitial Lung Disease (ILD) (244 participants)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | Mario Negri Institute for Pharmacological Research |
| Sponsor type | Academic and hospital |
| Study | Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan |
| NCT ID | NCT07828054 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Breast Cancer; Interstitial Lung Disease (ILD) |
| Intervention types | drug |
| Target enrollment | 244 |
| Posted | 2026-09-18 |
| Planned start | 2026-12-20 |
| Event | Newly registered study |
| Event date | 2026-09-18 |

## Why this score
- Phase 3: multi-site, larger budget.
- 244 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07828054). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.